This year marks the 10th year of the human papillomavirus (HPV) vaccination program in the United States. In 2006, the first HPV vaccine, quadrivalent HPV vaccine, was licensed by the US Food and Drug Administration and recommended by the Advisory Committee on Immunization Practices and the US Centers for Disease Control and Prevention (CDC). In subsequent years, 2 additional HPV vaccines were licensed, bivalent HPV vaccine in 2009 and 9-valent HPV vaccine in 2014.1 All 3 vaccines were initially licensed and recommended for use in a 3-dose series. In 2006, vaccination was recommended for girls at the age of 11 or 12 years with catch-up vaccination through the age of 26 years; in 2011, the United States was the first country to include boys and men in the routine HPV vaccination program. Following national introductions of HPV vaccination, significant declines in vaccine-type HPV prevalence, genital warts, and cervical precancers have been observed in the United States and other countries.2
Markowitz LE, Meites E, Unger ER. Two vs Three Doses of Human Papillomavirus Vaccine: New Policy for the Second Decade of the Vaccination Program. JAMA. 2016;316(22):2370–2372. doi:10.1001/jama.2016.16393
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: